MacroGenics

MARGENZA

Manufacturer:

MacroGenics

Margenza HCPCS:

J9353

HCPCS Code Descriptor:

Injection, margetuximab-cmkb, 5 mg

Category:

J Code

Margenza NDCs:

74527-0022-02, 74527-0022-03

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

74527-0022-03

About Margenza:

MARGENZA is an Oncology drug manufactured by MacroGenics and administered via the Intravenous route of administration. The J Code: J9353 is aligned to the drug MARGENZA.

ACCESS PRICING AND MORE BY REGISTERING

J9353 Added Date:

July 1, 2021

J9353 Effective Date:

July 1, 2021

J9353 Termination Date:

HCPCS Active

Margenza billing and coding information can be found through Macrogenics at the link below:
Margenza patient assistance information can be found through MARGENZA Access Support at the URL: https://www.margenzasupport.com/
MARGENZA prescribing information can be found at the link below:
Information regarding MARGENZA’s side effects can be found at MedlinePlus